These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 9200657)

  • 1. Optimization of glycemic control by insulin therapy decreases the proportion of small dense LDL particles in diabetic patients.
    Caixàs A; Ordóñez-Llanos J; de Leiva A; Payés A; Homs R; Pérez A
    Diabetes; 1997 Jul; 46(7):1207-13. PubMed ID: 9200657
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Electronegative low density lipoprotein subform is increased in patients with short-duration IDDM and is closely related to glycaemic control.
    Sánchez-Quesada JL; Pérez A; Caixàs A; Ordónmez-Llanos J; Carreras G; Payés A; González-Sastre F; de Leiva A
    Diabetologia; 1996 Dec; 39(12):1469-76. PubMed ID: 8960828
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High prevalence of small LDL particles in non-insulin-dependent diabetic patients with nephropathy.
    Hirano T; Naito H; Kurokawa M; Ebara T; Nagano S; Adachi M; Yoshino G
    Atherosclerosis; 1996 Jun; 123(1-2):57-72. PubMed ID: 8782837
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of insulin and sulfonylurea therapy, at the same level of blood glucose control, on low density lipoprotein subfractions in type 2 diabetic patients.
    Rivellese AA; Patti L; Romano G; Innelli F; Di Marino L; Annuzzi G; Iavicoli M; Coronel GA; Riccardi G
    J Clin Endocrinol Metab; 2000 Nov; 85(11):4188-92. PubMed ID: 11095452
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of insulin on body composition in patients with insulin-dependent and non-insulin-dependent diabetes.
    Sinha A; Formica C; Tsalamandris C; Panagiotopoulos S; Hendrich E; DeLuise M; Seeman E; Jerums G
    Diabet Med; 1996 Jan; 13(1):40-6. PubMed ID: 8741811
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Complementary insulin therapy improves blood glucose and serum lipid parameters in type 2 (non-insulin-dependent) diabetic patients. II. Effects on serum lipids, lipoproteins and apoproteins.
    Vaverková H; Chlup R; Ficker L; Novotny D; Bartek J
    Exp Clin Endocrinol Diabetes; 1997; 105 Suppl 2():74-7. PubMed ID: 9288551
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of glycemic optimization on electronegative low-density lipoprotein in diabetes: relation to nonenzymatic glycosylation and oxidative modification.
    Sánchez-Quesada JL; Pérez A; Caixàs A; Rigla M; Payés A; Benítez S; Ordóñez-Llanos J
    J Clin Endocrinol Metab; 2001 Jul; 86(7):3243-9. PubMed ID: 11443196
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Advanced lipoprotein profile disturbances in type 1 diabetes mellitus: a focus on LDL particles.
    Amor AJ; Castelblanco E; Hernández M; Gimenez M; Granado-Casas M; Blanco J; Soldevila B; Esmatjes E; Conget I; Alonso N; Ortega E; Mauricio D
    Cardiovasc Diabetol; 2020 Aug; 19(1):126. PubMed ID: 32772924
    [TBL] [Abstract][Full Text] [Related]  

  • 9. LDL from patients with well-controlled IDDM is not more susceptible to in vitro oxidation.
    Jenkins AJ; Klein RL; Chassereau CN; Hermayer KL; Lopes-Virella MF
    Diabetes; 1996 Jun; 45(6):762-7. PubMed ID: 8635650
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of type 2 diabetes on various electrophoretic characteristics of low-density lipoprotein particles in women.
    Blackburn P; Lemieux I; Lamarche B; Bergeron J; Perron P; Tremblay G; Gaudet D; Després JP
    Diabetologia; 2004 Dec; 47(12):2114-7. PubMed ID: 15602652
    [TBL] [Abstract][Full Text] [Related]  

  • 11. LDL subclass phenotypes and triglyceride metabolism in non-insulin-dependent diabetes.
    Feingold KR; Grunfeld C; Pang M; Doerrler W; Krauss RM
    Arterioscler Thromb; 1992 Dec; 12(12):1496-502. PubMed ID: 1450181
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Factors related to glycemic control in IDDM and insulin-treated NIDDM patients in current practice. A comparison of care policies. SIEMTIC Group. Studio Italiano Epidemiologico Multicentrico su Terapia Insulin e Controllo Metabolico.
    Garancini MP; Gallus G; Cucinotta D; Rossi A; Riccardi G
    Diabetes Care; 1997 Nov; 20(11):1659-63. PubMed ID: 9353604
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of nateglinide and glibenclamide on postprandial lipid and glucose metabolism in type 2 diabetes.
    Vakkilainen J; Mero N; Schweizer A; Foley JE; Taskinen MR
    Diabetes Metab Res Rev; 2002; 18(6):484-90. PubMed ID: 12469362
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inflammatory biomarkers in type 2 diabetic patients: effect of glycemic control and impact of LDL subfraction phenotype.
    Vinagre I; Sánchez-Quesada JL; Sánchez-Hernández J; Santos D; Ordoñez-Llanos J; De Leiva A; Pérez A
    Cardiovasc Diabetol; 2014 Feb; 13():34. PubMed ID: 24495560
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Premeal insulin lispro plus bedtime NPH or twice-daily NPH in patients with type 2 diabetes: acute postprandial and chronic effects on glycemic control and cardiovascular risk factors.
    Ceriello A; Del Prato S; Bue-Valleskey J; Beattie S; Gates J; de la Peña A; Malone J
    J Diabetes Complications; 2007; 21(1):20-7. PubMed ID: 17189870
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Elevated concentrations of soluble E-selectin and vascular cell adhesion molecule-1 in NIDDM. Effect of intensive insulin treatment.
    Albertini JP; Valensi P; Lormeau B; Aurousseau MH; Ferrière F; Attali JR; Gattegno L
    Diabetes Care; 1998 Jun; 21(6):1008-13. PubMed ID: 9614623
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lipoprotein alterations in hemodialysis: differences between diabetic and nondiabetic patients.
    González AI; Schreier L; Elbert A; Berg G; Beresan H; López G; Wikinski R
    Metabolism; 2003 Jan; 52(1):116-21. PubMed ID: 12524671
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interrelationship of antioxidative status, lipid peroxidation, and lipid profile in insulin-dependent and non-insulin-dependent diabetic patients.
    Cimbaljević B; Vasilijević A; Cimbaljević S; Buzadzić B; Korać A; Petrović V; Janković A; Korać B
    Can J Physiol Pharmacol; 2007 Oct; 85(10):997-1003. PubMed ID: 18066100
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacologic treatment of type 2 diabetic dyslipidemia.
    Moon YS; Kashyap ML
    Pharmacotherapy; 2004 Dec; 24(12):1692-713. PubMed ID: 15585439
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination of insulin and metformin in the treatment of type 2 diabetes.
    Wulffelé MG; Kooy A; Lehert P; Bets D; Ogterop JC; Borger van der Burg B; Donker AJ; Stehouwer CD
    Diabetes Care; 2002 Dec; 25(12):2133-40. PubMed ID: 12453950
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.